272 related articles for article (PubMed ID: 15060511)
1. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
5. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
7. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
8. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
[TBL] [Abstract][Full Text] [Related]
9. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
Shah J; Wesnes KA; Kovelesky RA; Henney HR
Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
[TBL] [Abstract][Full Text] [Related]
10. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
11. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
13. Grapefruit juice substantially increases plasma concentrations of buspirone.
Lilja JJ; Kivistö KT; Backman JT; Lamberg TS; Neuvonen PJ
Clin Pharmacol Ther; 1998 Dec; 64(6):655-60. PubMed ID: 9871430
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.
Neuvonen PJ; Jalava KM
Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
Darwish M; Chang S; Hellriegel ET
Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
[TBL] [Abstract][Full Text] [Related]
16. Human pharmacology of the methamphetamine stereoisomers.
Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
[TBL] [Abstract][Full Text] [Related]
17. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
[TBL] [Abstract][Full Text] [Related]
19. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney HR; Runyan JD
Int J Clin Pract; 2008 Feb; 62(2):314-24. PubMed ID: 18199279
[TBL] [Abstract][Full Text] [Related]
20. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
